Clinical trials have shown promising weight loss results with both medications, but more research is needed, particularly regarding the long-term effects of Tesofensine
Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors, which may lead to slightly greater weight loss in some patients
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M
Mice with AhR deficiency in microglia, a macrophage population in the brain, develop more severe EAE, with increased expression of pro-inflammatory genes and loss of IL-10 and transforming growth factor- (TGF-) expression
Lin, T.-C
This becomes especially important when you're in a calorie deficit and using GLP-1 therapy, as appetite suppression can sometimes make it harder to eat enough protein